BCG response and oncological outcomes in high risk nonmuscle invasive bladder cancer following previously treated upper tract urothelial carcinoma: A propensity-matched analysis
Our study indicates that BCG treatment may be less effective for NMIBC patients with a history of UTUC, with a higher risk of intravesical recurrences and disease progression. This is an important consideration when counselling patients for BCG treatment and overall prognostication.
Authors
- Wei Chong Tan (ORCID: https://orcid.org/0009-0004-8014-3294)
- Kae Jack Tay (ORCID: https://orcid.org/0000-0003-0365-1899)
- Syed A. Hussain (ORCID: https://orcid.org/0000-0003-1552-511X)
- Christopher Cheng (ORCID: https://orcid.org/0000-0003-0958-1115)
- Ravindran Kanesvaran (ORCID: https://orcid.org/0000-0002-2351-881X)
- Jason Yongsheng Chan (ORCID: https://orcid.org/0000-0002-4801-3703)
- Kenneth Chen (ORCID: https://orcid.org/0000-0002-3844-7567)
- Tsung Wen Chong (ORCID: https://orcid.org/0000-0002-6790-902X)
- Khi Yung Fong (ORCID: https://orcid.org/0000-0001-8194-0800)
- John Ong (ORCID: https://orcid.org/0000-0001-5103-7311)
- Timothy T. Lu (ORCID: https://orcid.org/0000-0003-1507-6473)
- Yu Guang Tan (ORCID: https://orcid.org/0000-0002-8166-0582)
- Blanche Lim
- Johan Chan (ORCID: https://orcid.org/0000-0002-4864-5225)
- Siying Tan
- Michael R. Abern
- J.S.P. Yuen
Institutions
- SingHealth (SG)
- Duke University (US)
- Singapore General Hospital (SG)
- Sheffield Teaching Hospitals NHS Foundation Trust (GB)
- National Cancer Centre Singapore (SG)
Publication Details
- Journal
- Urologic Oncology Seminars and Original Investigations
- Published
- 2025-04-22
- DOI
- https://doi.org/10.1016/j.urolonc.2025.03.026
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00